Pentadecanoic Acid for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Pentadecanoic Acid for Health & Longevity

Created on 09/26/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Pentadecanoic acid, a trace saturated fat from dairy and grazing-animal meat, is sold as a purified daily capsule promoted for healthy aging. People with more in their blood develop type 2 diabetes less often, though this comes from observation, not tests of the capsule. Small, short capsule trials show hints of better liver enzymes and cholesterol, but no long-term outcome data. Overall: low-risk, with an uncertain payoff. (Full Review)

Protocol

Manufacturer protocol
100 mg once daily
One capsule administered orally; this dose has not been tested in a published trial
Trial-based protocol
200–300 mg daily
Tested for 12 weeks; 300 mg is the highest studied dose
Time of day
Morning, single dose
Given each morning or with the first meal; food is assumed to aid absorption, though this is untested
Time to effect
Disease risk
Years
Any effect on disease risk would take years and remains unmeasured
Liver enzymes
By 12 weeks
Liver-enzyme changes appeared by 12 weeks in trials
Blood levels
12 weeks to 3–4 months
Blood levels rose by 12 weeks; red-cell membrane incorporation may take 3–4 months

Benefits

Contraindications
  • Propionic acidemia or methylmalonic acidemia, unless supervised by a metabolic specialist
  • Pregnancy or breastfeeding
  • Children and adolescents under 18 years
  • Dairy-fat route: LDL at or above 190 mg/dL or diagnosed familial hypercholesterolemia
  • Known hypersensitivity to any capsule ingredient
    •
Key Interactions
  • MAO-B inhibitors (selegiline, rasagiline, safinamide): Monitor, theoretical
  • Serotonergic drugs (SSRIs such as sertraline, escitalopram; triptans such as sumatriptan): Monitor, theoretical
  • Cannabinoid drugs (dronabinol, nabilone): Caution, theoretical
  • mTOR inhibitors and metformin (sirolimus, everolimus; metformin): Monitor, theoretical
  • Fat-absorption blockers (orlistat; cholestyramine, colesevelam): Monitor
  • Over-the-counter antihistamines (diphenhydramine, cetirizine, famotidine): Minor, theoretical
  • Supplements with additive effects (inulin, fermentable fibers, cannabidiol, berberine): Monitor
  • Dietary dairy fat: Caution when combined with supplements
  • Other interventions (rapamycin-based longevity protocols, calorie-restricted weight-loss diets): Monitor
    •

Risk & Side Effects

  • High: LDL cholesterol rise from dairy-fat sources
    •
  • Medium:
  • Low:
  • Speculative: Interactions with mood-active drugs; blunted muscle-building signaling
    •

Monitoring

Marker Target Why
Blood pentadecanoic acid Plasma above 5 µg/mL; 0.4–0.64% of membrane fatty acids (proposed) Confirms uptake
ALT Under 25 U/L Liver-cell stress
AST Under 25 U/L Liver and muscle stress
GGT Under 20 U/L Liver stress
LDL cholesterol Under 100 mg/dL Dairy-fat LDL effect
ApoB Under 80 mg/dL Cholesterol-carrying particle count
Hemoglobin Men 14–16 g/dL; women 13–15 g/dL Red-cell signal
RDW 11.5–13.0% Red-cell health
hs-CRP Under 1.0 mg/L Inflammation
HbA1c Under 5.4% Blood-sugar control
Ferritin 40–150 ng/mL Iron stores

Cadence: Baseline before starting; repeat at 12 weeks; then every 6–12 months while supplementation lasts, plus a lipid check 8–12 weeks after any change in dose or dairy intake

Qualitative Assessment

  • Energy and daytime fatigue
  • Sleep quality and duration
  • Digestive tolerance, such as stool changes or nausea
  • Mood and stress resilience
  • Skin and hair condition (marketed but untested claims)
  • Strength and training progress in people doing resistance exercise
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.